ANI Pharmaceuticals has added to its branded portfolio by acquiring several dermatology brands from Sandoz in the US.

The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.

Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.

Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.